European committee takes a second look at Alzheimer's drug and …
19 hours ago · A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.. Biogen said Thursday that the drug, known in the U.S. as Leqembi, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use as a treatment for early Alzheimer’s disease.
Biogen’s Decision to Discontinue Alzheimer’s Drug | alz.org
CHICAGO, Jan. 31, 2024 — Despite today’s announcement from Biogen, the Alzheimer’s Association is extremely optimistic about the future of Alzheimer’s treatments; a new era that started with the Food and Drug Administration (FDA) accelerated approval of Aduhelm in 2021.
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
22 hours ago · The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the ...
Biogen discontinues Alzheimer’s medication Aduhelm - CNN
Jan 31, 2024 · CNN — The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments,...
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows …
Oct 30, 2024 · (Bloomberg) -- Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new Alzheimer’s treatment.
Biogen to stop selling controversial Alzheimer's drug Aduhelm - NBC News
Jan 31, 2024 · Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago.
Biogen to Realign Resources for Alzheimer's Disease Franchise
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth.
Biogen to shut down controversial Alzheimer's drug Aduhelm | AP News
Jan 31, 2024 · Biogen will stop selling its Alzheimer’s treatment Aduhelm. The drug was once seen as a potential blockbuster but it stumbled after its launch a few years ago. The drugmaker also said Wednesday that it will end a study of the drug needed for full approval from the Food and Drug Administration.
Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm
Jan 31, 2024 · The drug maker Biogen said on Wednesday it would abandon its ownership rights to Aduhelm, an Alzheimer’s drug that had provoked fierce criticism of the company and regulators after it was...
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated ... - Biogen
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease. January 6, 2023. PDF Version. Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta …